Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > First I've heard of it....
View:
Post by 2021Gamble on Mar 30, 2023 8:37pm

First I've heard of it....

And the Jan 23rd update on the PP distribution shows that even then that it would have been a planned shortfall as only $60k was allocated to F.C.

There has been ample 'update' news releases where this could have been buried, but I haven't seen it ... Wonder whether it's buried in a past md&a,but I don't recall reading 'bout this previous to this
Comment by biggdogg on Mar 31, 2023 2:42pm
FC is low priority. They need to put every dime into sales. And not just one product to market, but all products to market. FC is done, proven and ready to mine. They will never get FC financed until they prove the economics. That is the strategy the company has been promoting. It is mining 101, the issue with FC is there are no mine analysts, no bankers, no engineers who understand a mining ...more  
Comment by lscfa on Apr 01, 2023 12:10am
I disagree. Why produce a product with the same inputs as competitors (e.g. Chinese raw materials) and blow your brains out trying to grab market share? That will lead to bankruptcy. According to the PEA the average grade of BaSO4 is 2.71% (96,200 tonnes from 3,553,000 tonnes mined over 9 years).  Of the 96,200 tonnes of BaSO4 only 2767 tonnes was to be used for Pharma over the 9 years. The ...more  
Comment by WarrantOfficer on Apr 01, 2023 3:02pm
I fully concur Iscfa. Francis Creek gives Voyageur the pricing and Canadian sourced advantage. An army cut off from their supply lines is going nowhere. Francis Creek accessibility is critical to our Strategic planning. Financing is paramount. 
Comment by WarrantOfficer on Apr 01, 2023 3:02pm
I fully concur Iscfa. Francis Creek gives Voyageur the pricing and Canadian sourced advantage. An army cut off from their supply lines is going nowhere. Francis Creek accessibility is critical to our Strategic planning. Financing is paramount.@
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1